Seronegative rheumatoid arthritis: response to treatment with disease modifying antirheumatic drugs compared to seropositive variants of the disease
Summary. Summary. In this clinical study the effectiveness of non-biological disease modifying antirheumatic drugs (DMARDs) in patients with seronegative rheumatoid arthritis (RA) compared to seropositive (by rheumatoid factor (RF) and/or antibodies to cyclic citrullinated peptide (aCCP)) RA was determined. It was found that the clinical response to DMARDs therapy is more than two times better and radiological progression is much slower in seronegative patients compared to seropositive, integrated clinical/radiological disease control and clinical/radiological remission are achieved more often in seronegative patients then in seropositive (by both RF and aCCP or just aCCP). Clinical and radiological results of DMARDs treatment in RF-positive patients without aCCP is comparable with seronegative patients and significantly better then in aCCP-positive patients (regardless of RF presence), that equals this subgroup to seronegative RA.
No Comments » Add your